These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 6387216)

  • 1. [Unusual bile acids].
    Sasaki Y
    Nihon Rinsho; 1984 Jul; 42(7):1548-54. PubMed ID: 6387216
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cerebrotendinous xanthomatosis and bile acids].
    Hoshita T
    Nihon Rinsho; 1984 Jul; 42(7):1664-70. PubMed ID: 6492409
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
    Lirussi F; Okolicsanyi L
    Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pathophysiology of cholestasis with special reference to primary biliary cirrhosis.
    Jansen PL
    Baillieres Best Pract Res Clin Gastroenterol; 2000 Aug; 14(4):571-83. PubMed ID: 10976015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Abnormal bile acids in benign recurrent intrahepatic cholestasis].
    Endo T
    Nihon Rinsho; 1984 Jul; 42(7):1618-24. PubMed ID: 6492403
    [No Abstract]   [Full Text] [Related]  

  • 6. [Intrahepatic cholestasis due to biochemical errors of bile acids. II. Clinical and therapeutic aspects].
    Lovisetto P; Raviolo P
    Minerva Med; 1994 Dec; 85(12):639-46. PubMed ID: 7854557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bile secretory failure: recent concepts of the pathogenesis of intrahepatic cholestasis.
    Simon FR; Reichen J
    Prog Liver Dis; 1982; 7():195-206. PubMed ID: 7051146
    [No Abstract]   [Full Text] [Related]  

  • 8. [Intrahepatic cholestasis caused by biochemical errors of bile acids. Part I --Nosographic, pathogenetic, diagnostic features].
    Lovisetto P; Raviolo P
    Minerva Med; 1994 Nov; 85(11):589-96. PubMed ID: 7808683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study on the mechanism of an experimental immunological intrahepatic cholestasis model.
    Shin T; Mizoguchi Y; Kioka K; Kobayashi K; Morisawa S
    Osaka City Med J; 1992 Nov; 38(2):111-25. PubMed ID: 1488254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bile acid synthesis.
    Salen G; Shefer S
    Annu Rev Physiol; 1983; 45():679-85. PubMed ID: 6847167
    [No Abstract]   [Full Text] [Related]  

  • 11. [The bile acids in primary biliary cirrhosis. Comparison with other hepatic diseases].
    Rautureau M; Lemonnier F; Chevrel B
    Rev Int Hepatol; 1966; 16(2):193-205. PubMed ID: 5947842
    [No Abstract]   [Full Text] [Related]  

  • 12. Primary bile acid kinetics in patients with primary biliary cirrhosis and in normal subjects.
    Williams CN; MacDonald IA; Park-Dincsoy H
    Clin Invest Med; 1979; 2(1):29-40. PubMed ID: 509806
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pathophysiology of cholestasis: correlation between bile acid metabolism and liver damage].
    Stiehl A
    Z Gastroenterol; 1992 Mar; 30 Suppl 1():46-8. PubMed ID: 1449016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of determining bile acids in the blood of patients with chronic cholestatic hepatitis and primary biliary cirrhosis].
    Radchenko VG; Mekhanik ZI
    Vrach Delo; 1985 May; (5):26-8. PubMed ID: 4013219
    [No Abstract]   [Full Text] [Related]  

  • 15. Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport.
    Paulusma CC; Groen A; Kunne C; Ho-Mok KS; Spijkerboer AL; Rudi de Waart D; Hoek FJ; Vreeling H; Hoeben KA; van Marle J; Pawlikowska L; Bull LN; Hofmann AF; Knisely AS; Oude Elferink RP
    Hepatology; 2006 Jul; 44(1):195-204. PubMed ID: 16799980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis.
    Batta AK; Salen G; Mirchandani R; Tint GS; Shefer S; Batta M; Abroon J; O'Brien CB; Senior JR
    Am J Gastroenterol; 1993 May; 88(5):691-700. PubMed ID: 8480734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: a study of bile acid metabolism.
    Crosignani A; Podda M; Bertolini E; Battezzati PM; Zuin M; Setchell KD
    Hepatology; 1991 Jun; 13(6):1076-83. PubMed ID: 2050325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic handling of bile salts and protein in the rat during intrahepatic cholestasis.
    Goldsmith MA; Huling S; Jones AL
    Gastroenterology; 1983 May; 84(5 Pt 1):978-86. PubMed ID: 6832571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of the intractable cholestasis of primary biliary cirrhosis.
    Bloomer JR; Ghent CN
    Semin Liver Dis; 1981 Nov; 1(4):345-53. PubMed ID: 7051313
    [No Abstract]   [Full Text] [Related]  

  • 20. Bile acids and their sulphated and glucuronidated derivatives in bile, plasma, and urine of children with intrahepatic cholestasis: effects of phenobarbital treatment.
    Stiehl A; Becker M; Czygan P; Fröhling W; Kommerell B; Rotthauwe HW; Senn M
    Eur J Clin Invest; 1980 Aug; 10(4):307-16. PubMed ID: 6775958
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.